Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 inhibitors

被引：0
|
作者：
Henrich, T. J. [1 ,2 ]
Lewine, N. [3 ]
Lee, S-H [1 ,4 ]
Rao, S. [3 ]
Berro, R. [5 ]
Greaves, W. [6 ]
Gulick, R.
Tsibris, A. [2 ,7 ]
Moore, J. [5 ]
Kuritzkes, D. [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Harvard Univ, Cambridge, MA 02138 USA
[4] Pusan Natl Univ, Pusan, South Korea
[5] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[6] Schering Plough Res Inst, Kenilworth, NJ USA
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
ANTIVIRAL THERAPY | 2011年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
46
引用
收藏
页码：A59 / A59
页数：1
相关论文
共 50 条
  • [21] CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro
    Salkowitz, JR
    Bruse, SE
    Meyerson, H
    Valdez, H
    Mosier, DE
    Harding, CV
    Zimmerman, PA
    Lederman, MM
    CLINICAL IMMUNOLOGY, 2003, 108 (03) : 234 - 240
  • [22] CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1
    Lorenzen, Thore
    Stoehr, Albrecht
    Walther, Irene
    Plettenberg, Andreas
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 419 - 425
  • [23] CCR5 antagonist-resistant HIV-1 entry kinetics as a function of CD4 and CCR5 surface expression
    Putcharoen, O.
    Lee, S-H
    Henrich, T. J.
    Vanichanan, J.
    Kuritzkes, D. R.
    Tsibris, A. M. N.
    ANTIVIRAL THERAPY, 2011, 16 : A64 - A64
  • [24] CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1
    Bredeek, U. Fritz
    Harbour, Michael J.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 427 - 434
  • [25] Choosing CCR5 or Rev siRNA in HIV-1
    Arteaga, HJ
    Hinkula, J
    van Dijk-Härd, I
    Dilber, MS
    Wahren, B
    Christensson, B
    Mohamed, AJ
    Smith, CIE
    NATURE BIOTECHNOLOGY, 2003, 21 (03) : 230 - 231
  • [26] Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors
    Kazmierski, W
    Bifulco, N
    Yang, HB
    Boone, L
    DeAnda, F
    Watson, C
    Kenakin, T
    BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (13) : 2663 - 2676
  • [27] CCR5 monoclonal antibodies for HIV-1 therapy
    Olson, William C.
    Jacobson, Jeffrey M.
    CURRENT OPINION IN HIV AND AIDS, 2009, 4 (02) : 104 - 111
  • [28] HIV-1 infection and CCR5Δ32 homozygosis
    Ballana, Ester
    Este, Jose A.
    FUTURE VIROLOGY, 2012, 7 (07) : 653 - 658
  • [29] Choosing CCR5 or Rev siRNA in HIV-1
    H. Jose Arteaga
    Jorma Hinkula
    Iris van Dijk-Härd
    M. Sirac Dilber
    Britta Wahren
    Birger Christensson
    Abdalla J. Mohamed
    C. I. Edvard Smith
    Nature Biotechnology, 2003, 21 : 230 - 231
  • [30] CCR5 as target for HIV-1 gene therapy
    Nazari, Reza
    Joshi, Sadhna
    CURRENT GENE THERAPY, 2008, 8 (04) : 264 - 272
12345